



## UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO
09/420,433	10/12/1999	DAVID SIDRANSKY	ЛНU1180-1	2810
75	90 03/02/2005		EXAM	INER
Lisa A. Haile			JOHANNSEN, DIANA B	
Gray Cary Ware & Freidenrich LLP 4365 Executive Drive			ART UNIT	PAPER NUMBER
SUITE 1100 San Diego, CA 92121-2133			1634	
			DATE MAILED: 03/02/2005	

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)
Advisory Action	09/420,433 SIDRANSKY, DAVID	
Before the Filing of an Appeal Brief	Examiner	Art Unit
	Diana B. Johannsen	1634
The MAILING DATE of this communication ap	pears on the cover sheet with	the correspondence address
THE REPLY FILED <u>02 February 2005</u> FAILS TO PLACE TH	IS APPLICATION IN CONDITION	ON FOR ALLOWANCE.
<ol> <li>The reply was filed after a final rejection, but prior to fil applicant must timely file one of the following replies: ( application in condition for allowance; (2) a Notice of A Request for Continued Examination (RCE) in compliar time periods:</li> </ol>	an amendment, affidavit, or appeal (with appeal fee) in compace with 37 CFR 1.114. The rep	other evidence, which places the bliance with 37 CFR 41.31; or (3) a
a) The period for reply expires 3 months from the mailing date		
b) The period for reply expires on: (1) the mailing date of this A event, however, will the statutory period for reply expire later		
Examiner Note: If box 1 is checked, check either box (a) or		
MONTHS OF THE FINAL REJECTION. See MPEP 706.0 extensions of time may be obtained under 37 CFR 1.136(a). The date	7(f).	
neen filed is the date for purposes of determining the period of extension of ER 1.17(a) is calculated from: (1) the expiration date of the shortened above, if checked. Any reply received by the Office later than three more armed patent term adjustment. See 37 CFR 1.704(b).	statutory period for reply originally se	t in the final Office action; or (2) as set forth
The reply was filed after the date of filing a Notice of A was filed on A brief in compliance with 37 CFF Appeal (37 CFR 41.37(a)), or any extension thereof (3 Appeal has been filed, any reply must be filed within the MENDMENTS - ルカ くらとま 13 ちもしのい	R 41.37 must be filed within two 7 CFR 41.37(e)), to avoid dismi le time period set forth in 37 CF	months of the date of filing the Notic ssal of the appeal. Since a Notice of R 41.37(a).
<ul> <li>The proposed amendment(s) filed after a final rejection</li> <li>(a) They raise new issues that would require further</li> <li>(b) They raise the issue of new matter (see NOTE be</li> </ul>	consideration and/or search (seelow);	ee NOTE below);
(c) They are not deemed to place the application in lappeal; and/or	petter form for appeal by materi	ally reducing or simplifying the issue
(d) They present additional claims without canceling NOTE: (See 37 CFR 1.116 and 41.33(a	· -	ally rejected claims.
4. The amendments are not in compliance with 37 CFR		lon-Compliant Amendment (PTOL-3)
5. Applicant's reply has overcome the following rejection		ion-compilant Amendment (1 102-0)
6. Newly proposed or amended claim(s) would be		parate, timely filed amendment cance
the non-allowable claim(s).  7. For purposes of appeal, the proposed amendment(s): how the new or amended claims would be rejected is purposed to the claim(s) is (or will be) as follows:		☐ will be entered and an explanation
Claim(s) allowed:		
Claim(s) objected to: Claim(s) rejected:		
Claim(s) rejected Claim(s) withdrawn from consideration:		
AFFIDAVIT OR OTHER EVIDENCE		
The affidavit or other evidence filed after a final action,     because applicant failed to provide a showing of good.		

later. In no /ITHIN TWO on fee have e under 37 set forth in (b) duce any e of Appeal e Notice of tice of ause e issues for TOL-324). t canceling olanation of be entered because applicant failed to provide a showing of good and sufficient reasons why the affidavit or other evidence is necessary and was not earlier presented. See 37 CFR 1.116(e). 9. The affidavit or other evidence filed after the date of filing a Notice of Appeal, but prior to the date of filing a brief, will not be entered because the affidavit or other evidence failed to overcome all rejections under appeal and/or appellant fails to provide a showing a good and sufficient reasons why it is necessary and was not earlier presented. See 37 CFR 41.33(d)(1). 10. The affidavit or other evidence is entered. An explanation of the status of the claims after entry is below or attached. REQUEST FOR RECONSIDERATION/OTHER 11. 🔯 The request for reconsideration has been considered but does NOT place the application in condition for allowance because: see Attachment. Note the attached Information Disclosure Statement(s). (PTO/SB/08 or PTO-1449) Paper No(s). 13. Other: It is noted that while applicant's response included a complete set of claims, no amendments to the claims were made/proposed. Diana B. Johannsen **Primary Examiner** Art Unit: 1634

U.S. Patent and Trademark Office

Application/Control Number: 09/420,433 Page 2

Art Unit: 1634

## Attachment to Advisory Action

Applicant's arguments have been thoroughly considered but are not persuasive. 1. First, it is noted that while Applicant argues that the claims are limited to mutant target nucleic acids that are "present in the primary neoplasm" and to the detection of such nucleic acids in a "histologically normal specimen," in fact only claims 1 and 20 (and claims dependent therefrom) require the former, while none of the claims require the latter. Claims 1, 20, and 25 (and claims dependent therefrom) do require a specimen that "does not exhibit morphological characteristics indicative of neoplastic pathology." However, in view of this, Applicant's argument that the claims are directed to the detection of nucleic acids in a specimen that contains neoplastic cells is confusing and non-persuasive; if the specimen of the claimed methods includes neoplastic cells, the specimen cannot entirely lack "morphological characteristics indicative of neoplastic pathology," as the claims recite. While Applicant's specification does discuss the use of samples that are "histologically negative" for tumor by, e.g., light microscopy, the features of the invention on which Applicant's present arguments rely are not features of the invention presently claimed. Although the claims are interpreted in light of the specification, limitations from the specification are not read into the claims. See In re-Van Geuns, 988 F.2d 1181, 26 USPQ2d 1057 (Fed. Cir. 1993).

## Conclusion

2. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Diana B. Johannsen whose telephone number is

Page 3

Application/Control Number: 09/420,433

Art Unit: 1634

571/272-0744. The examiner can normally be reached on Monday-Friday, 7:30 am-4:00 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, W. Gary Jones can be reached at 571/272-0745. The fax phone number for the organization where this application or proceeding is assigned is 571/273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Diana B. Johannsen Primary Examiner Art Unit 1634